Skip to main content
. 2017 Sep 28;8:254. doi: 10.3389/fendo.2017.00254

Table 1.

Thyroid dysfunction during Alemtuzumab treatment in patients with multiple sclerosis (MS).

Patients and dysfunctions (%)
Patients with thyroid dysfunction in the 216 patients cohort 34

  • Graves’ hyperthyroidism

  • Hypothyroidism

  • Destructive thyroiditis

  • 22.4

  • 7.4

  • 4.2
Type of dysfunction in the 73 affected patients

  • Graves’ hyperthyroidism

  • Hypothyroidism

  • Destructive thryoiditis

  • Unknown

  • 65.8

  • 20.5

  • 10.3

  • 1.4
Number of events of thyroid dysfunction between the 102 recorded events

  • Single

  • Multiple

  • 70.0

  • 30.0
Type of event among the 102 recorded events

  • Graves’ hyperthyroidism

    • ◦

      Overt

    • ◦

      Subclinical

  • Hypothyroidism

  • Destructive thryoiditis

  • Unknown

  • Graves’ orbitophaty

  • 58.8

  • 81.7

  • 18.3

  • 29.4

  • 9.8

  • 2.0

  • 6.0

Results of the CAMMS223 study as categorized by Daniels et al. (42).